DENVER, Colo., Apr 23, 2024 (247marketnews.com)- Adicet Bio, Inc. (Nasdaq:ACET) stated that a new preclinical data highlighting ADI-270 was selected for an oral presentation at the ASGCT 27th Annual Meeting on May 10, 2024 in the Targeted Gene and Cell Therapy session, co-chaired by Adicet Bio's Chief Scientific Officer, Blake Aftab, Ph.D.

“We look forward to sharing new preclinical data at ASGCT further illustrating ADI-270's robust anti-tumor activity with a differentiated method for targeting CD70 across multiple solid and hematologic cancers,” stated Blake Aftab, Ph.D., Chief Scientific Officer of Adicet Bio. “ADI-270 is a next-generation CAR T cell therapy candidate designed to capitalize on potent tumor infiltration associated with the gamma delta T cell platform. ADI-270 is further enhanced with armoring to address suppressive tumor microenvironments and to address clearance by host T cells. In preclinical studies, ADI-270 demonstrated enhanced functional persistence and potency, including unique contribution of innate anti-tumor immunity, compared to multiple clinically relevant benchmarks in cancers expressing CD70. Supported by these encouraging data, we look forward to advancing ADI-270's clinical development and remain on track to file an IND in renal cell carcinoma this quarter.”

The post Adicet Bio to Present Preclinical Data Supporting IND Readiness for ADI-270 at ASGCT Annual Meeting appeared first on 24/7 MarketNews.

COMTEX_451345558/2900/2024-04-24T11:16:25